Top Markets
#1 GoPlus Security GoPlus Security +31.51%
#2 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.70%
#3 Status Status +17.55%
#4 Wrapped NXM Wrapped NXM +14.47%
#5 BankrCoin BankrCoin +11.13%
#6 Pons Pons +10.73%
#7 Bedrock Bedrock +10.01%
#8 Ontology Gas Ontology Gas +9.25%
#9 DMT-NAT DMT-NAT +8.78%
#10 o1.exchange o1.exchange +7.41%
Coin of the day
GoPlus Security GoPlus Security
Innstillinger
Språk
NORSK
Valuta
USD
Tema
20/20 Biolabs Inc. 20/20 Biolabs Inc.

20/20 Biolabs Inc.

AIDX
Rangering i aksjer #33866
20/20 GeneSystems, Inc. operates as a clinical laboratory testing company... 20/20 GeneSystems, Inc. operates as a clinical laboratory testing company focused on cancer screening and viral testing services. The company provides multi-cancer early detection blood testing, including a test called OneTest, and offers viral testing services such as rapid COVID-19 test kits, including the Assure COVID-19 IgG/IgM rapid test. It operates the Clinical Lab Innovation Axcelerator (CLIAx), a shared laboratory facility that supports diagnostic test developers in bringing products to the U.S. market. The company also delivers its cancer screening algorithm technology through a software as a service (SaaS) platform in partnership with healthcare providers and supports diagnostic startups by offering access to shared laboratory space and resources. The company was founded in 2000 and is based in Gaithersburg, Maryland.
Aksjekurs
$0.5475
Sist synkronisert: 2026-08-14
Markedsverdi
$6.71M
Endring (1 dag)
5.57%
Endring (1 år)
-
Land
US
Handel 20/20 Biolabs Inc. (AIDX)

Kategori

Healthcare
P/E-forhold for 20/20 Biolabs Inc. (AIDX)
P/E-forhold per 2026 TTM: 0
Ifølge 20/20 Biolabs Inc. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/E-forhold (TTM) 0. Ved slutten av 2026 hadde selskapet en P/E på 0.
P/E-forholdshistorikk for 20/20 Biolabs Inc. fra 2026 til 2026
P/E-forhold ved slutten av hvert år
År P/E-forhold Endre
Ikke nok data for de angitte datoene.
P/E-forhold for lignende selskaper eller konkurrenter
Selskap P/E-forhold Forskjell i P/E-forhold Land
HCA Healthcare, Inc. HCA Healthcare, Inc.
HCA Healthcare, Inc.
HCA.US
 13.51 -
US
Fresenius SE & Co. KGaA Fresenius SE & Co. KGaA
Fresenius SE & Co. KGaA
FRE.DE
 - -
DE
Dr. Sulaiman Al Habib Medical Services Group Company Dr. Sulaiman Al Habib Medical Services Group Company
Dr. Sulaiman Al Habib Medical Services Group Company
4013.SR
 33.05 -
SA
Tenet Healthcare Corporation Tenet Healthcare Corporation
Tenet Healthcare Corporation
THC.US
 10.26 -
US
IHH Healthcare Berhad IHH Healthcare Berhad
IHH Healthcare Berhad
5225.KL
 - -
MY
Hvordan lese en P/E-ratio?

Pris/inntjening-forholdet (P/E) måler forholdet mellom aksjekursen og inntjening per aksje.
En lav men positiv P/E indikerer høy inntjening sammenlignet med nåværende verdsettelse, og kan tyde på at selskapet er undervurdert. En høy negativ (nær 0) P/E indikerer store tap.

Selskaper med P/E over 30 eller negativ betraktes vanligvis som "vekstaksjer", hvor investorer forventer vekst eller fremtidig lønnsomhet.

Selskaper med en positiv P/E under 10 anses vanligvis som "verdiaksjer", det vil si at selskapet allerede er lønnsomt, men har begrenset vekstpotensial.